Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Yates S, Weiss J, Sneider A, Geramita E, Murthy G, Badar T, Im A, Lin C, Cheng W, Abaza Y, Swaroop A, Winer E, Litzow M, Atallah E, Patel A, Shallis R. Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Haematologica 2025 PMID: 40702896, DOI: 10.3324/haematol.2025.288085.Peer-Reviewed Original ResearchTreatment start dateAcute myeloid leukemiaHypomethylating agentsOverall survivalEuropean LeukemiaNetMyeloid leukemiaAML disease biologyDiagnosis of acute myeloid leukemiaAML-directed therapyDiagnosis to initiationRetrospective cohort studyMyeloid malignanciesRisk diseaseSurvival outcomesOncologic emergencyCohort studyAcademic centersMulti-centerNeoplastic diseasePatientsDisease biologyRisk classificationDiagnosisLeukemiaSurvival
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply